6.
Saad M, Seoudy H, Frank D
. Challenging Anatomies for TAVR-Bicuspid and Beyond. Front Cardiovasc Med. 2021; 8:654554.
PMC: 8076502.
DOI: 10.3389/fcvm.2021.654554.
View
7.
Pibarot P, Ternacle J, Jaber W, Salaun E, Dahou A, Asch F
. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. J Am Coll Cardiol. 2020; 76(16):1830-1843.
DOI: 10.1016/j.jacc.2020.08.049.
View
8.
Horsted Thyregod H, Jorgensen T, Ihlemann N, Steinbruchel D, Nissen H, Kjeldsen B
. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. 2024; 45(13):1116-1124.
PMC: 10984572.
DOI: 10.1093/eurheartj/ehae043.
View
9.
Mirsadraee S, Sellers S, Duncan A, Hamadanchi A, Gorog D
. Bioprosthetic valve thrombosis and degeneration following transcatheter aortic valve implantation (TAVI). Clin Radiol. 2020; 76(1):73.e39-73.e47.
DOI: 10.1016/j.crad.2020.08.015.
View
10.
Sa M, Van den Eynde J, Simonato M, Cavalcanti L, Doulamis I, Weixler V
. Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement: An Updated Meta-Analysis. JACC Cardiovasc Interv. 2021; 14(2):211-220.
DOI: 10.1016/j.jcin.2020.10.020.
View
11.
Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed K
. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017; 389(10087):2383-2392.
DOI: 10.1016/S0140-6736(17)30757-2.
View
12.
Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G
. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007; 28(2):230-68.
DOI: 10.1093/eurheartj/ehl428.
View
13.
Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodes-Cabau J
. Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration. J Am Coll Cardiol. 2017; 70(8):1013-1028.
DOI: 10.1016/j.jacc.2017.07.715.
View
14.
Stacchino C, Bona G, Bonetti F, Rinaldi S, Della Ciana L, GRIGNANI A
. Detoxification process for glutaraldehyde-treated bovine pericardium: biological, chemical and mechanical characterization. J Heart Valve Dis. 1998; 7(2):190-4.
View
15.
Human P, Bezuidenhout D, Aikawa E, Zilla P
. Residual Bioprosthetic Valve Immunogenicity: Forgotten, Not Lost. Front Cardiovasc Med. 2022; 8:760635.
PMC: 8764456.
DOI: 10.3389/fcvm.2021.760635.
View
16.
David T, Ivanov J, Armstrong S, Feindel C, Cohen G
. Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg. 2001; 121(2):268-77.
DOI: 10.1067/mtc.2001.112208.
View
17.
Bourguignon T, Bouquiaux-Stablo A, Candolfi P, Mirza A, Loardi C, May M
. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015; 99(3):831-7.
DOI: 10.1016/j.athoracsur.2014.09.030.
View
18.
Kwiecinski J, Tzolos E, Cartlidge T, Fletcher A, Doris M, Bing R
. Native Aortic Valve Disease Progression and Bioprosthetic Valve Degeneration in Patients With Transcatheter Aortic Valve Implantation. Circulation. 2021; 144(17):1396-1408.
PMC: 8542078.
DOI: 10.1161/CIRCULATIONAHA.121.056891.
View
19.
Desai P, Goel S, Kleiman N, Reardon M
. Transcatheter Aortic Valve Implantation: Long-Term Outcomes and Durability. Methodist Debakey Cardiovasc J. 2023; 19(3):15-25.
PMC: 10198228.
DOI: 10.14797/mdcvj.1201.
View
20.
Williams D, Bezuidenhout D, de Villiers J, Human P, Zilla P
. Long-Term Stability and Biocompatibility of Pericardial Bioprosthetic Heart Valves. Front Cardiovasc Med. 2021; 8:728577.
PMC: 8473620.
DOI: 10.3389/fcvm.2021.728577.
View